SLC5A2 and hydrops fetalis: Sodium–glucose co-transporter 2 (SGLT2) inhibitors were initially developed as oral antidiabetic agents; however, due to expression of SGLT2 in cardiac tissue, they have demonstrated cardiovascular benefits in the setting of HF with different LVEF [50].